Articles related to BLEEDING/BLOOD DISORDERS

In this study, more than 12,000 patients 18 years and older with hospitalization for extremity fracture were randomized to LWMH or aspirin. Rates of DVT were 1.7% and 2.5%, respectively. PE, bleeding complications, and other SAEs were similar across groups. Death occurred in 0.73% and 0.78% respectively for LWMH and aspirin.

The risk of symptomatic intracranial hemorrhage was lower among the 832 patients receiving direct oral anticoagulant treatment in this cohort study involving 33,207 patients with ischemic stroke who received intravenous thrombolysis at 64 centers in Europe, Asia, Australia, and New Zealand when compared to controls who received no anticoagulation. This outcome held true across subgroups and various selection methodologies.

A 61-year-old woman taking methotrexate for RA, which has been stable for several years, has new monoclonal protein discovered on routine follow-up. Physical and routine labs are normal. Electrophoresis displays an IgG κ monoclonal protein spike of 0.8 g/dL. What is the proper follow-up?

Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Combination therapy with once-daily oral gonadotropin-releasing hormone-receptor antagonist relugolix plus estradiol and norethindrone acetate in a 12-week course resulted in a significant reduction in bleeding in more than 70% of those in the therapy arms versus less than 20% for the placebo groups.

The first treatment for light-chain amyloidosis was approved by the FDA in 2021. Daratumumab-based regimens produce profound hematologic and organ responses, providing a new therapeutic foundation. Early detection, correct fibril typing, the challenges of the very advanced patient, and the lack of therapies to remove amyloid deposits are all being researched but remain elusive.

The timing of re-initiation of antithrombotic therapy needs to be individualized based on the severity of the bleed, among other factors. This article reviews the issue and offers tools and guidelines for determining if and when to restart antiplatelet and oral anticoagulant therapy.